CRISPR & Gene Editing— Companies & Signals
The CRISPR & Gene Editing investment theme centers on companies developing and commercializing precise DNA modification technologies to address a wide range of diseases and agricultural challenges. This transformative field holds the potential for significant therapeutic breakthroughs and advancements in sustainable food production, representing a substantial long-term growth opportunity. 37 public companies above the $50M floor. Last 90 days: 23 red 8-Ks, 0 insider cluster-buys, 3 running hot in the press.
37
Companies
23
Red 8-Ks · 90d
0
Insider clusters
3
🔥 Media-hot
Companies in CRISPR & Gene Editing
Refine in search →| # | Ticker | Company | Sector | Mkt cap | 1D | 5D | Volume | Heat | Signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PRME | Prime Medicine, Inc. | Healthcare | $501.2M | +8.4% | +10.4% | 5.3M | — | red 8-K |
| 2 | CRSP | CRISPR Therapeutics AG | Healthcare | $4.9B | +2.6% | +3.7% | 1.8M | ⚡ | red 8-K |
| 3 | DTIL | PRECISION BIOSCIENCES INC | Healthcare | $157.4M | +8.6% | +11.9% | 775K | — | red 8-K |
| 4 | EDIT | Editas Medicine, Inc. | Healthcare | $383.7M | +12.3% | +14.3% | 3.0M | — | red 8-K |
| 5 | RVTY | REVVITY, INC. | Healthcare | $11.1B | -1.6% | +12.3% | 2.0M | 🔥 | |
| 6 | CRBU | Caribou Biosciences, Inc. | Healthcare | $158.2M | +5.4% | +7.9% | 2.8M | — | |
| 7 | CBUS | Cibus, Inc. | Materials | $93.9M | +5.2% | +10.0% | 251K | — | red 8-K |
| 8 | NTLA | Intellia Therapeutics, Inc. | Healthcare | $1.7B | -0.4% | +5.5% | 5.6M | ⚡ | |
| 9 | MXCT | MAXCYTE, INC. | Healthcare | $120.0M | 0.0% | +5.1% | 1.2M | — | red 8-K |
| 10 | NKTX | Nkarta, Inc. | Healthcare | $204.6M | +0.7% | +2.1% | 577K | — | |
| 11 | IPSC | Century Therapeutics, Inc. | Healthcare | $405.8M | +3.9% | +4.8% | 1.9M | — | red 8-K |
| 12 | ALLO | Allogene Therapeutics, Inc. | Healthcare | $655.8M | +4.2% | +5.7% | 14.7M | — | red 8-K |
| 13 | NGNE | Neurogene Inc. | Healthcare | $459.8M | +0.8% | +0.1% | 545K | — | red 8-K |
| 14 | IONS | IONIS PHARMACEUTICALS INC | Healthcare | $12.1B | -0.6% | +6.3% | 2.8M | — | red 8-K |
| 15 | TRDA | Entrada Therapeutics, Inc. | Healthcare | $250.8M | -0.4% | +9.1% | 240K | — | red 8-K |
| 16 | SRPT | Sarepta Therapeutics, Inc. | Healthcare | $1.6B | +1.0% | -3.6% | 3.8M | — | red 8-K |
| 17 | PGEN | PRECIGEN, INC. | Healthcare | $1.6B | +1.0% | +10.0% | 6.3M | — | red 8-K |
| 18 | TWST | Twist Bioscience Corp | Healthcare | $4.7B | -1.5% | +15.5% | 1.7M | — | |
| 19 | WVE | Wave Life Sciences Ltd. | Healthcare | $1.1B | -2.6% | -7.9% | 2.7M | — | |
| 20 | PRQR | ProQR Therapeutics N.V. | Healthcare | $151.7M | +19.6% | -2.7% | 2.6M | — | |
| 21 | UTHR | UNITED THERAPEUTICS Corp | Healthcare | $23.2B | +0.4% | +1.2% | 420K | ⚡ | red 8-K |
| 22 | FHTX | Foghorn Therapeutics Inc. | Healthcare | $245.4M | +15.2% | +16.3% | 389K | — | |
| 23 | SANA | Sana Biotechnology, Inc. | Healthcare | $745.8M | +0.9% | +2.7% | 2.5M | — | red 8-K |
| 24 | CTVA | Corteva, Inc. | Consumer Staples | $50.9B | +0.9% | +5.7% | 3.1M | 🔥 | red 8-K |
| 25 | ZSQR | Z Squared Inc. | Financials | $561.9M | -6.3% | -20.7% | 671K | — | red 8-K |
| 26 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | Healthcare | $1.8B | -0.9% | +3.7% | 10.7M | — | |
| 27 | EWTX | Edgewise Therapeutics, Inc. | Healthcare | $3.7B | -1.3% | +12.1% | 1.9M | ⚡ | |
| 28 | RXRX | RECURSION PHARMACEUTICALS, INC. | Healthcare | $1.7B | +4.8% | +16.0% | 22.9M | — | red 8-K |
| 29 | AGIO | AGIOS PHARMACEUTICALS, INC. | Healthcare | $1.8B | +0.4% | +8.4% | 772K | — | red 8-K |
| 30 | BBIO | BridgeBio Pharma, Inc. | Healthcare | $13.1B | +2.5% | +4.5% | 3.3M | — | red 8-K |
| 31 | SUZ | Suzano S.A. | Materials | $10.2B | -0.7% | -6.6% | 3.5M | — | |
| 32 | A | AGILENT TECHNOLOGIES, INC. | Healthcare | $36.7B | -2.3% | +5.0% | 2.0M | 🔥 | red 8-K |
| 33 | MGTX | MeiraGTx Holdings plc | Healthcare | $888.1M | +3.5% | +9.2% | 683K | — | |
| 34 | LYEL | Lyell Immunopharma, Inc. | Healthcare | $315.0M | +9.8% | +6.5% | 200K | — | |
| 35 | ORKA | Oruka Therapeutics, Inc. | Healthcare | $4.2B | +2.1% | +8.3% | 1.7M | — | |
| 36 | OTLK | Outlook Therapeutics, Inc. | Healthcare | $181.3M | -1.2% | -7.7% | 7.9M | — | red 8-K |
| 37 | FATE | FATE THERAPEUTICS INC | Healthcare | $240.1M | +15.2% | +12.6% | 5.9M | — | red 8-K |
Membership is matched by keyword from companies’ SEC business descriptions (10-K Item 1) — deterministic, not AI inference. May not be exhaustive; not investment advice.